1
|
Pastor J, Vega-Zelaya L, Torres CV, Navas-García M, López-Manzanares L. [Towards a positive physiological definition of the deep brain nuclei in humans]. Rev Neurol 2022; 75:369-376. [PMID: 36514203 DOI: 10.33588/rn.7512.2022187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Using microelectrodes for recording purposes in deep brain stimulation (DBS) has proven to be very useful. Their efficiency can be improved by characterising the properties of extracellular action potentials (EAPs). PATIENTS AND METHODS We analysed the records of nine patients who underwent surgery for epilepsy or aggressiveness under general anaesthesia. The properties of the EAPs of the centromedian, ventral intermediate, ventrocaudal and posteromedial hypothalamic nuclei of the thalamus have been determined. RESULTS We have analysed 706 thalamic and 142 hypothalamic cells. The proportion of cell types was found to be specific to each cell nucleus. The most frequent cell type was P1P2N1 (59.5%), followed by N1P1N2 (23.1%). The first phase of the EAP is highly variable. The properties of the EAP phases of the same morphology differ greatly from one nucleus to another. CONCLUSIONS We have shown that several deep brain nuclei have properties that are specific to the morphology of the EAPs. This will allow for improved localisation of these nuclei during DBS.
Collapse
Affiliation(s)
- J Pastor
- Hospital Universitario de La Princesa, 28006 Madrid, España.,Instituto de Investigación Biomédica. Hospital Universitario de La Princesa, Madrid, España
| | - L Vega-Zelaya
- Hospital Universitario de La Princesa, 28006 Madrid, España.,Instituto de Investigación Biomédica. Hospital Universitario de La Princesa, Madrid, España
| | - C V Torres
- Hospital Universitario de La Princesa, Madrid, España.,Instituto de Investigación Biomédica. Hospital Universitario de La Princesa, Madrid, España
| | - M Navas-García
- Hospital Universitario de La Princesa, 28006 Madrid, España.,Instituto de Investigación Biomédica. Hospital Universitario de La Princesa, Madrid, España
| | | |
Collapse
|
2
|
Brandts I, Cánovas M, Tvarijonaviciute A, Llorca M, Vega A, Farré M, Pastor J, Roher N, Teles M. Nanoplastics are bioaccumulated in fish liver and muscle and cause DNA damage after a chronic exposure. Environ Res 2022; 212:113433. [PMID: 35580665 DOI: 10.1016/j.envres.2022.113433] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 04/22/2022] [Accepted: 05/03/2022] [Indexed: 06/15/2023]
Abstract
The extent of the widespread, planetary contamination by plastic waste is difficult to fully capture. Nanoplastics (NPs) are currently in the center of research concerning plastic litter, both for the analytical challenges they pose and for their potential to provoke hazardous effects in organisms. However, there are still many unanswered questions in this multidisciplinary field, with a crucial missing piece being the quantification of NPs in fish tissues after in vivo exposures. Another relevant question that is still greatly unexplored is how a chronic exposure to NPs will affect fish health. This study aims to provide answers to both of these relevant knowledge gaps. To this end, goldfish (Carassius auratus) were exposed to 44 nm polystyrene (PS)-NPs via water for 30 days. Following the exposure, gastrointestinal tract, liver and muscle were sampled for PS-NPs analysis by means of size exclusion chromatography coupled to high resolution mass spectrometry. PS-NPs were detected in all liver and muscle samples of exposed fish, with higher concentrations in liver than in muscle, whereas no PS-NPs were detected in the gastrointestinal tract. Nevertheless, exposure to PS-NPs did not induce changes in hematology parameters nor in cortisol and glucose levels in plasma. On the other hand, even a relatively low concentration of PS-NPs was able to cause DNA damage, measured by an increase in erythrocyte nuclear abnormalities, suggesting that PS-NPs can reach the cell nucleus and cause genotoxicity. These results show for the first time that PS-NPs find their way to fish muscle after chronic exposure, where they bioaccumulate, but do not alter fish survival nor hematological or physiological stress indicators. The accumulation of PS-NPs in fish muscle can represent a threat to human health as a possible route of exposure to small-sized plastics. The present results in a model fish species open windows for future studies in edible fish species.
Collapse
Affiliation(s)
- I Brandts
- Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - M Cánovas
- Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - A Tvarijonaviciute
- Interdisciplinary Laboratory of Clinical Analysis Interlab-UMU, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, Murcia, 30100, Spain
| | - M Llorca
- Institute of Environmental Assessment and Water Research (IDAEA-CSIC), Barcelona, Spain
| | - A Vega
- Institute of Environmental Assessment and Water Research (IDAEA-CSIC), Barcelona, Spain
| | - M Farré
- Institute of Environmental Assessment and Water Research (IDAEA-CSIC), Barcelona, Spain
| | - J Pastor
- Department of Animal Medicine and Surgery, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - N Roher
- Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - M Teles
- Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain.
| |
Collapse
|
3
|
Jimenez L, Amenabar C, Mayoral-Varo V, Mackenzie TA, Ramos MC, Silva A, Calissi G, Grenho I, Blanco-Aparicio C, Pastor J, Megías D, Ferreira BI, Link W. mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity. Molecules 2022; 27:molecules27175414. [PMID: 36080182 PMCID: PMC9457944 DOI: 10.3390/molecules27175414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 08/10/2022] [Accepted: 08/22/2022] [Indexed: 11/16/2022] Open
Abstract
Forkhead box O (FOXO) proteins are transcription factors involved in cancer and aging and their pharmacological manipulation could be beneficial for the treatment of cancer and healthy aging. FOXO proteins are mainly regulated by post-translational modifications including phosphorylation, acetylation and ubiquitination. As these modifications are reversible, activation and inactivation of FOXO factors is attainable through pharmacological treatment. One major regulatory input of FOXO signaling is mediated by protein kinases. Here, we use specific inhibitors against different kinases including PI3K, mTOR, MEK and ALK, and other receptor tyrosine kinases (RTKs) to determine their effect on FOXO3 activity. While we show that inhibition of PI3K efficiently drives FOXO3 into the cell nucleus, the dual PI3K/mTOR inhibitors dactolisib and PI-103 induce nuclear FOXO translocation more potently than the PI3Kδ inhibitor idelalisib. Furthermore, specific inhibition of mTOR kinase activity affecting both mTORC1 and mTORC2 potently induced nuclear translocation of FOXO3, while rapamycin, which specifically inhibits the mTORC1, failed to affect FOXO3. Interestingly, inhibition of the MAPK pathway had no effect on the localization of FOXO3 and upstream RTK inhibition only weakly induced nuclear FOXO3. We also measured the effect of the test compounds on the phosphorylation status of AKT, FOXO3 and ERK, on FOXO-dependent transcriptional activity and on the subcellular localization of other FOXO isoforms. We conclude that mTORC2 is the most important second layer kinase negatively regulating FOXO activity.
Collapse
Affiliation(s)
- Lucia Jimenez
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Carlos Amenabar
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Victor Mayoral-Varo
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Thomas A. Mackenzie
- Fundación MEDINA, Health Sciences Technology Park, Avda. del Conocimiento 34, 18016 Granada, Spain
| | - Maria C. Ramos
- Fundación MEDINA, Health Sciences Technology Park, Avda. del Conocimiento 34, 18016 Granada, Spain
| | - Andreia Silva
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, 8005-139 Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, 8005-139 Faro, Portugal
| | - Giampaolo Calissi
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Inês Grenho
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, 8005-139 Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, 8005-139 Faro, Portugal
| | - Carmen Blanco-Aparicio
- Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
| | - Joaquin Pastor
- Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
| | - Diego Megías
- Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
| | - Bibiana I. Ferreira
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, 8005-139 Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, 8005-139 Faro, Portugal
- Correspondence: (B.I.F.); (W.L.)
| | - Wolfgang Link
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
- Correspondence: (B.I.F.); (W.L.)
| |
Collapse
|
4
|
Jimenez L, Silva A, Calissi G, Grenho I, Monteiro R, Mayoral-Varo V, Blanco-Aparicio C, Pastor J, Bustos V, Bracher F, Megías D, Ferreira BI, Link W. Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3. J Gerontol A Biol Sci Med Sci 2022; 77:1485-1493. [PMID: 34508571 PMCID: PMC9373959 DOI: 10.1093/gerona/glab265] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Indexed: 12/01/2022] Open
Abstract
Several chemical compounds including natural products have been suggested as being effective against age-related diseases or as beneficial for a healthy life. On the other hand, forkhead box O (FOXO) proteins are emerging as key cellular components associated with extreme human longevity. FOXO proteins are mainly regulated by posttranslational modifications and as these modifications are reversible, activation and inactivation of FOXO are attainable through pharmacological treatment. Here, we questioned whether a panel of compounds with known health-beneficial properties has the capacity to induce the activity of FOXO factors. We show that resveratrol, a phytoalexin present in grapes and other food products, the amide alkaloid piperlongumine found in the fruit of the long pepper, and the plant-derived β-carboline compound harmine induced nuclear translocation of FOXO3. We also show that piperlongumine and harmine but not resveratrol activate FOXO-dependent transcription. We determined the half maximal effective concentration (EC50) values for resveratrol, piperlongumine, and harmine for FOXO translocation, and analyzed their inhibitory impact on chromosomal maintenance 1 (CRM1)-mediated nuclear export and the production of reactive oxygen species (ROS). We also used chemical biology approach and Western blot analysis to explore the underlying molecular mechanisms. We show that harmine, piperlongumine, and resveratrol activate FOXO3 independently of phosphoinositide 3-kinase (PI3K)/AKT signaling and the CRM1-mediated nuclear export. The effect of harmine on FOXO3 activity is at least partially mediated through the inhibition of dual-specificity tyrosine (Y) phosphorylationregulated kinase 1A (DYRK1A) and can be reverted by the inhibition of sirtuins (SIRTs).
Collapse
Affiliation(s)
- Lucia Jimenez
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - Andreia Silva
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Giampaolo Calissi
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - Inês Grenho
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Rita Monteiro
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Victor Mayoral-Varo
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | | | - Joaquin Pastor
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Franz Bracher
- Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany
| | - Diego Megías
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| |
Collapse
|
5
|
Arévalo-Sáenz A, López-Manzanares L, Navas-García M, Pastor J, Vega-Zelaya L, Torres CV. Deep brain stimulation in Parkinson's disease: analysis of brain fractional anisotropy differences in operated patients. Rev Neurol 2022; 74:125-134. [PMID: 35148421 DOI: 10.33588/rn.7404.2021196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Deep brain stimulation (DBS) of the subthalamic nucleus is currently an evidence-based therapeutic option for motor symptoms in patients with Parkinson's disease (PD), although other non-motor symptoms can be affected by stimulation. AIM Our objective is to evaluate the global changes in the connectivity of the large-scale structural network in PD patients that have obtained a benefit from subthalamic DBS. SUBJECTS AND METHODS Retrospective study of 31 subjects: 7 PD patients with subthalamic DBS (group A), 12 age and gender-matched non-operated PD (B) and 12 healthy controls (C). All subjects had undergone a 1.5 T brain MRI with DTI. DICOM images were processed with the FSL5.0 software and TBSS tool. RESULTS The study group comprised 23 men and 8 women. No statistically significant differences in age, gender, scores on the HandY scale and mean follow-up between group A and B were found, and in age and gender between groups A and C. Statistical analysis revealed differences in the fractional anisotropy of the different groups in certain areas: bilateral corticospinal tract, anterior thalamic radiations, bilateral fronto-occipital fascicle, both superior longitudinal fascicles, and left inferior longitudinal fascicle. CONCLUSIONS In our series, PD patients treated with bilateral subthalamic DBS showed a significantly higher fractional anisotropy in widespread areas of the cerebral white matter; suggesting that neuromodulation produces connectivity changes in different neural networks.
Collapse
Affiliation(s)
| | | | - M Navas-García
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - J Pastor
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - L Vega-Zelaya
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - C V Torres
- Hospital Universitario de La Princesa, 28006 Madrid, España
| |
Collapse
|
6
|
Abstract
Every surgeon starts the training with suturing, which can be very confusing as most of the senior surgeons have their own style, approach, tricks and different rules to follow. It is hard for residents and medical students to know what is an evidence-based rule that should be followed and what is a personal trick of their teacher that can be modified. We provide a review of current data on surgical suturing with all the reasons for specific techniques. Parameters of the correct skin suture, practical guide and all the complications are mentioned in the text.
Collapse
Affiliation(s)
- V Kunc
- Department of Anatomy, Second Faculty of Medicine, Charles University, Prague
| | - J Pastor
- Department of Anatomy, Second Faculty of Medicine, Charles University, Prague.,Third Department of Surgery, First Faculty of Medicine, Charles University and Motol University Hospital, Prague
| | - A Haluza
- Department of Anatomy, Second Faculty of Medicine, Charles University, Prague
| | - D Kachlik
- Department of Anatomy, Second Faculty of Medicine, Charles University, Prague.,Department of Health Care Studies, College of Polytechnics, Jihlava. Czech Republic
| |
Collapse
|
7
|
Zhu L, Blanco-Aparicio C, Bertero L, Soffietti R, Weiss T, Muñoz J, Sepúlveda J, Weller M, Pastor J, Valiente M. OS06.7A METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
The diagnosis of brain metastasis involves high morbidity and mortality and remains an unmet clinical need in spite of being the most common tumor in the brain. Exclusion of these cancer patients from clinical trials is a major cause of their limited therapeutic options.
MATERIAL AND METHODS
We report a novel drug-screening platform (METPlatform) based on organotypic cultures which allows identifying effective anti-metastasis agents in the presence of the organ microenvironment. We have applied this approach to clinically relevant stages of brain metastasis using both experimental models and human tumor tissue (by performing patient-derived organotypic cultures - PDOCs -). We have also used METPlatform to perform unbiased proteomics of brain metastases in situ to identify potential novel mediators of this disease and explore resistance mechanisms to targeted therapy. Finally, we have exploited METPlatform as “avatars” to predict response to therapy in patients with primary brain tumors.
RESULTS
We identified heat shock protein 90 (HSP90) as a promising therapeutic target for brain metastasis. DEBIO-0932, a blood-brain barrier permeable HSP90 inhibitor, shows high potency against mouse and human brain metastases from different primary origin and oncogenomic profile at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis of brain metastases treated with the chaperone inhibitor revealed non-canonical clients of HSP90 as potential novel mediators of brain metastasis and actionable mechanisms of resistance driven by autophagy. Combined therapy using HSP90 and autophagy inhibitors showed synergistic effects compared to sublethal concentrations of each monotherapy, demonstrating the potential of METPlatform to design and test rationale combination therapies to target metastasis more effectively. Finally, we show that brain tumor PDOCs predict the response of the corresponding patient to standard of care, thus proving the potential of METPlatform for improving personalized care in cancer.
CONCLUSION
Our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is fully compatible with human samples and questions the rationale of excluding patients with brain metastasis from clinical trials. We envision that METPlatform will be established as a clinically relevant strategy to personalize the management of metastatic disease in the brain and elsewhere.
Collapse
Affiliation(s)
- L Zhu
- Spanish National Cancer Research Center, Madrid, Spain
| | | | - L Bertero
- University and City of Health and Science Hospital, Turin, Italy
| | - R Soffietti
- University and City of Health and Science Hospital, Turin, Italy
| | - T Weiss
- University Hospital Zurich, Zurich, Switzerland
| | - J Muñoz
- Spanish National Cancer Research Center, Madrid, Spain
| | - J Sepúlveda
- Hospital Universitario Doce de Octubre, Madrid, Spain
| | - M Weller
- University Hospital Zurich, Zurich, Switzerland
| | - J Pastor
- Spanish National Cancer Research Center, Madrid, Spain
| | - M Valiente
- Spanish National Cancer Research Center, Madrid, Spain
| |
Collapse
|
8
|
Parra JL, Pastor J, Comelles F, Manresa A, Bosch P. Studies of Biosurfactants Obtained from Olive Oil / Biotenside aus Olivenöl. TENSIDE SURFACT DET 2021. [DOI: 10.1515/tsd-1990-270509] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Decarriere G, Pastor J, Demoulin D, Mouterde G, Lukas C, Combe B, Mercier G, Morel J, Daien C. OP0214 IMPACT OF A MULTI-MORBIDITY SCREENING AND PREVENTION PROGRAM IN CHRONIC INFLAMMATORY RHEUMATIC DISEASES ON THE ONE-YEAR HOSPITALIZATION RATE BASED ON AN ANALYSIS OF THE FRENCH NATIONAL HEALTH DATABASE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:A screening program for multimorbidities started in 2014 at the Montpellier University Hospital for primary prevention in patients with chronic inflammatory rheumatic diseases (IRD).Objectives:The objective of this work was to assess the impact of this program on morbidity by comparing the hospitalization rate of those patients in the year following the screening to the one of patients with IRD who did not benefit from this program.Methods:Patients with IRD who benefit from the screening program in 2015, 2016 and 2017 were identified in the French national health database PMSI and matched to 3 controls living in the same area on age, sex, type of IRD, use of intravenous (IV) biologic (b) DMARDs and index date. The exclusion criteria were subjects in secondary prevention identified as history of myocardial infarction in the previous 5 years or use of antiplatelet therapy. The primary outcome was the rate of all-cause hospitalization in the following year. The secondary endpoints were hospitalizations for another reason than IRD (“non-IRD”) including those for cardiovascular [CV] events and major fractures. Hospitalization rates were compared between the two groups in the year after screening (or index date) and also between the year preceding screening and the year after for each group. Univariate and multivariate odds ratios (CI95%) were calculated, taking into account the medical history (hypertension, diabetes, heart failure, CV disease, COPD, major fractures in the 5 years preceding the index date) and hospitalizations in the previous year.Results:486 patients were identified and matched with 1458 controls. 67.08% had rheumatoid arthritis and 21.81% spondyloarthritis; 7% of them had IV bDMARDs. Unscreened patients had more hypertension (19% vs 10.1%), diabetes (9% vs 4.9%), heart failure (2.3% vs 0.4%) and “non-IRD” hospitalizations (78.5% vs 72.2%) in the 5 years preceding the index date. In the year following the index date, the percentages of “all causes” and “non-IRD” hospitalizations were significantly higher in non-screened than in screened patients (n = 1944, 64.8% versus 51%, Chi2 test, p <0.001; and 47.1% versus 37.9%, p <0.001 respectively). 17 (1.17%) cardiovascular events occurred in non-screened versus 2 (0.41%) in screened patients (n = 1944, Chi2 test, p = 0.14). There was no difference in the occurrence of CV events or major fractures between the 2 groups. In multivariate analysis, screening was associated with a 49% (0.51 [0.41-0.64]) reduction in “all causes” hospitalization and a 27% (0, 73 [0.58-0.91]) decrease in “non-IRD” hospitalization, with no difference for CV or fracture cardiological events. The risk factors associated with “non-IRD” hospitalization were: history of “non-IRD” hospitalization in the previous year (2.26 [1.63-3.13]), IV bDMARDs (1.69 [1, 14-2.53]) and age> 70 years (1.44 [1.02-2.03] vs <50 years). Hospitalization in the previous year for “all causes” or “non-IRD” was associated with rehospitalization in the following year in the non-screened group (p <0.001), but not in the screened group (p = 0.750 and p = 0.066 respectively).Conclusion:Our screening and prevention program was associated with a reduction in hospitalizations in the following year and a decrease in the risk of re-hospitalization compared to unscreened patients with IRD. This suggests a positive impact of performing systematic screening for multi-morbidities in IRD patients.Acknowledgements:We thank Pfizer for their financial supportDisclosure of Interests:guillaume decarriere: None declared, Jenica PASTOR: None declared, David DEMOULIN: None declared, Gael Mouterde Speakers bureau: Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Grant/research support from: Pfizer, Cédric Lukas Speakers bureau: Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, Consultant of: Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, Grant/research support from: Pfizer, Novartis and Roche-Chugai, Bernard Combe Speakers bureau: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Consultant of: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Grant/research support from: Novartis, Pfizer, and Roche-Chugai, Grégoire Mercier: None declared, Jacques Morel Speakers bureau: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Consultant of: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Grant/research support from: Novartis, Pfizer, and Roche-Chugai, Claire Daien Speakers bureau: Pfizer, Roche-Chugai, Fresenius, BMS, MSD, Lilly, Novartis, Galapagos, Consultant of: Abivax, Abbbvie, BMS, Roche-Chugai, Grant/research support from: Pfizer, roche-chugai, fresenius, MSD
Collapse
|
10
|
Muro-García I, Vieira A, Vega L, Pastor J, de Toledo M. [Response to perampanel in a patient with chronic post-hypoxic myoclonus]. Rev Neurol 2021; 73:111-113. [PMID: 34291448 DOI: 10.33588/rn.7303.2021098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Chronic post-hypoxic myoclonus is a condition in which the predominant clinical picture is myoclonus following hypoxic brain damage, usually due to cardiorespiratory arrest. It is a condition that is usually treated with antiepileptic drugs, in most cases with a modest clinical response. CASE REPORT We report the case of a patient who started with jerking movements, compatible with myoclonus in the four limbs and the face the day after recovering from a cardiorespiratory arrest. An electroencephalogram was performed during which the myoclonias were recorded with no electrical correlates. During admission, and in successive visits after discharge, different antiepileptic treatments were tried for the myoclonias, which were refractory and affected the patient's quality of life. Two years after onset, treatment with perampanel up to a dose of 4 mg was initiated and the patient reported a significant clinical improvement, as evidenced in the visits. CONCLUSIONS Perampanel may be an effective alternative for the treatment of myoclonias in patients with chronic post-hypoxic myoclonus.
Collapse
Affiliation(s)
- I Muro-García
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - A Vieira
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - L Vega
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - J Pastor
- Hospital Universitario de La Princesa, 28006 Madrid, España
| | - M de Toledo
- Hospital Universitario de La Princesa, 28006 Madrid, España
| |
Collapse
|
11
|
Vega-Zelaya L, Ezquiaga E, Giogi González M, Pastor J. An induction test employing nonphysiologic manoeuvres for the diagnosis of a functional movement disorder. Neurología (English Edition) 2020. [DOI: 10.1016/j.nrleng.2019.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
12
|
Kennedy SP, O'Neill M, Cunningham D, Morris PG, Toomey S, Blanco-Aparicio C, Martinez S, Pastor J, Eustace AJ, Hennessy BT. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene 2020; 39:3028-3040. [PMID: 32042115 PMCID: PMC7118022 DOI: 10.1038/s41388-020-1202-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 01/20/2020] [Accepted: 01/30/2020] [Indexed: 11/09/2022]
Abstract
The proviral integration of Moloney virus (PIM) family of protein kinases are overexpressed in many haematological and solid tumours. PIM kinase expression is elevated in PI3K inhibitor-treated breast cancer samples, suggesting a major resistance pathway for PI3K inhibitors in breast cancer, potentially limiting their clinical utility. IBL-302 is a novel molecule that inhibits both PIM and PI3K/AKT/mTOR signalling. We thus evaluated the preclinical activity of IBL-302, in a range of breast cancer models. Our results demonstrate in vitro efficacy of IBL-302 in a range of breast cancer cell lines, including lines with acquired resistance to trastuzumab and lapatinib. IBL-302 demonstrated single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines. We have also shown the in vivo single-agent efficacy of IBL-302 in the subcutaneous BT-474 and HCC-1954 xenograft model in BALB/c nude mice. The combination of trastuzumab and IBL-302 significantly increased the anti-proliferative effect in HER2+ breast cancer cell line, and matched trastuzumab-resistant line, relative to testing either drug alone. We thus believe that the novel PIM and PI3K/mTOR inhibitor, IBL-302, represents an exciting new potential treatment option for breast cancer, and that it should be considered for clinical investigation.
Collapse
Affiliation(s)
- Sean P Kennedy
- Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons Ireland, Smurfit Building Beaumont Hospital, Beaumont, Dublin, Ireland.
| | - Michael O'Neill
- Inflection Biosciences, Anglesea House, Blackrock, Dublin, Ireland
| | | | - Patrick G Morris
- Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons Ireland, Smurfit Building Beaumont Hospital, Beaumont, Dublin, Ireland.,Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland
| | - Sinead Toomey
- Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons Ireland, Smurfit Building Beaumont Hospital, Beaumont, Dublin, Ireland
| | - Carmen Blanco-Aparicio
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Sonia Martinez
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Joaquin Pastor
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Alex J Eustace
- Molecular Therapeutics for Cancer in Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - Bryan T Hennessy
- Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons Ireland, Smurfit Building Beaumont Hospital, Beaumont, Dublin, Ireland.,Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland.,Cancer Trials Ireland, Innovation House, Old Finglas Road, Botanic, Dublin, Ireland
| |
Collapse
|
13
|
Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Aparicio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma. EMBO Mol Med 2020; 12:e11749. [PMID: 31916402 PMCID: PMC6949485 DOI: 10.15252/emmm.201911749] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
14
|
Pastor J, Libánský P, Adámek S, Lischke R, Naňka O. History of thyroid surgery. Rozhl Chir 2020; 99:476-480. [PMID: 33445944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The authors present an outline of the development of thyroid surgery from the ancient times to the beginning of the 20th century, when the defini-tive surgical technique have been developed and the physiologic and pathopfysiologic consequences of thyroid resections have been described. The key representatives, as well as the contribution of the most influential czech surgeons are mentioned.
Collapse
|
15
|
Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nat Commun 2019; 10:5428. [PMID: 31780656 PMCID: PMC6883072 DOI: 10.1038/s41467-019-13315-x] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Accepted: 11/04/2019] [Indexed: 12/21/2022] Open
Abstract
Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling. To proactively identify resistance mechanisms in ALK-positive neuroblastoma (NB), we herein employ genome-wide CRISPR activation screens of NB cell lines treated with brigatinib or ceritinib, identifying PIM1 as a putative resistance gene, whose high expression is associated with high-risk disease and poor survival. Knockdown of PIM1 sensitizes cells of differing MYCN status to ALK inhibitors, and in patient-derived xenografts of high-risk NB harboring ALK mutations, the combination of the ALK inhibitor ceritinib and PIM1 inhibitor AZD1208 shows significantly enhanced anti-tumor efficacy relative to single agents. These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status.
Collapse
Affiliation(s)
- Ricky M Trigg
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.,Functional Genomics, Medicinal Science & Technology, GlaxoSmithKline, Stevenage, SG1 2NY, UK
| | - Liam C Lee
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.,Amgen, Thousand Oaks, CA, 91320, USA
| | - Nina Prokoph
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - Leila Jahangiri
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - C Patrick Reynolds
- Cancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, 79430, USA
| | - G A Amos Burke
- Department of Paediatric Oncology, Box 181, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, UK
| | - Nicola A Probst
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - Miaojun Han
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.,OncoSec, San Diego, CA, 92121, USA
| | - Jamie D Matthews
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - Hong Kai Lim
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - Eleanor Manners
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - Sonia Martinez
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Joaquin Pastor
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Carmen Blanco-Aparicio
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Olaf Merkel
- Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria
| | - Ines Garces de Los Fayos Alonso
- Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria
| | - Petra Kodajova
- Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, 1210, Austria
| | - Simone Tangermann
- Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, 1210, Austria
| | - Sandra Högler
- Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, 1210, Austria
| | - Ji Luo
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20814, USA
| | - Lukas Kenner
- Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.,Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, 1210, Austria.,Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Boltzmanngasse 20, Medical University of Vienna, Vienna, 1090, Austria
| | - Suzanne D Turner
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block level 3, Box 231, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
| |
Collapse
|
16
|
Evangelista T, Labasse C, Beuvin M, Brochier G, Madelaine A, Pastor J, Romero N. CONGENITAL MYOPATHIES: RYR1 AND TITIN. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma. EMBO Mol Med 2019; 11:e10058. [PMID: 31310053 PMCID: PMC6685085 DOI: 10.15252/emmm.201810058] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 06/04/2019] [Accepted: 06/24/2019] [Indexed: 11/12/2022] Open
Abstract
The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL‐302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL‐302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. IBL‐302 was more effective than single PI3K inhibition in vitro, and IBL‐302 treatment of neuroblastoma patient‐derived xenograft (PDX) cells induced apoptosis, differentiated tumor cells, and decreased N‐Myc protein levels. IBL‐302 further enhanced the effect of the common cytotoxic chemotherapies cisplatin, doxorubicin, and etoposide. Global genome, proteome, and phospho‐proteome analyses identified crucial biological processes, including cell motility and apoptosis, targeted by IBL‐302 treatment. While IBL‐302 treatment alone reduced tumor growth in vivo, combination therapy with low‐dose cisplatin inhibited neuroblastoma PDX growth. Complementing conventional chemotherapy treatment with PIM/PI3K/mTOR inhibition has the potential to improve clinical outcomes and reduce severe late effects in children with high‐risk neuroblastoma.
Collapse
Affiliation(s)
- Sofie Mohlin
- Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Karin Hansson
- Department of Laboratory Medicine, Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden
| | - Katarzyna Radke
- Department of Laboratory Medicine, Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden
| | - Sonia Martinez
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Carmen Blanco-Apiricio
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Cristian Garcia-Ruiz
- Department of Laboratory Medicine, Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden
| | - Charlotte Welinder
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - Javanshir Esfandyari
- Department of Laboratory Medicine, Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden
| | | | - Joaquin Pastor
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Kristoffer von Stedingk
- Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden.,Department of Oncogenomics, University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Daniel Bexell
- Department of Laboratory Medicine, Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden
| |
Collapse
|
18
|
Bravo C, Nuñez M, Pastor J, Moya S, Campos L, Valenzuela A, Moscoso C, Palma C, Barrientos G. Mandibular condylar hyperplasia: clinical, histopathologic and demographic consideration in a series of 13 cases, retrospective study. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Sanz-Garcia A, Perez-Romero M, Pastor J, Sola RG, Vega-Zelaya L, Monasterio F, Torrecilla C, Vega G, Pulido-Rivas P, Ortega GJ. [Is it possible to extract intracranial pressure information based on the EEG activity?]. Rev Neurol 2019; 68:375-383. [PMID: 31017290 DOI: 10.33588/rn.6809.2018179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
INTRODUCTION The capability of the electroencephalography (EEG) of recording the bioelectrical activity of the brain has made of it a fundamental tool for the evaluation of the patient's neurological condition. In recent years, moreover, it has also begun to be used in obtaining information for other kind of variables, as the ones related with the cerebral hemodynamics. AIM To study the potential relationship between the EEG activity and the intracranial pressure (ICP) in patients suffering from traumatic brain injury and subarachnoid hemorrhage, during their stay at the intensive care unit. PATIENTS AND METHODS Twenty-one adult patients (10 women) were included in the present observational prospective cohort study. They suffered from either traumatic brain injury or subarachnoid hemorrhage, requiring continuous EEG and ICP monitoring. In every patient, Granger causality between spectral functions of the EEG and the ICP was evaluated. Temporal windows of 10 minute were used to evaluate whether a causal relationship between those variables exist or not. In all of the cases, several days of continuous recording and assessment were performed. RESULTS In most patients and during most of the time, Granger causality turns out to be significant in the direction from the EEG to the ICP, meaning that the EEG dynamics actually leads the ICP dynamics. CONCLUSIONS The present work provides useful information and shed light in discovering a hidden relationship between the ICP and EEG dynamics. The potential use of this relationship could lead to develop a medical device to measure ICP in a non-invasive fashion.
Collapse
Affiliation(s)
- A Sanz-Garcia
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - M Perez-Romero
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - J Pastor
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - R G Sola
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - L Vega-Zelaya
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - F Monasterio
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - C Torrecilla
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - G Vega
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - P Pulido-Rivas
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - G J Ortega
- Hospital Universitario de la Princesa, Madrid, Espana
| |
Collapse
|
20
|
Hervás A, Pastor J, González C, Jové J, Gómez A, Casaña M, Villafranca E, Mengual JL, Muñoz V, Henriquez I, Muñoz J, Collado E, Clemente J. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database. Clin Transl Oncol 2018; 21:900-909. [PMID: 30536208 DOI: 10.1007/s12094-018-02000-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 11/24/2018] [Indexed: 01/05/2023]
Abstract
PURPOSE To retrospectively assess outcomes and to identify prognostic factors in patients diagnosed with intermediate-risk (IR) prostate cancer (PCa) treated with primary external beam radiotherapy (EBRT). MATERIALS AND METHODS Data were obtained from the multi-institutional Spanish RECAP database, a population-based prostate cancer registry in Spain. All IR patients (NCCN criteria) who underwent primary EBRT were included. The following variables were assessed: age; prostate-specific antigen (PSA); Gleason score; clinical T stage; percentage of positive biopsy cores (PPBC); androgen deprivation therapy (ADT); and radiotherapy dose. The patients were stratified into one of three risk subcategories: (1) favourable IR (FIR; GS 6, ≤ T2b or GS 3 + 4, ≤ T1c), (2) marginal IR (MIR; GS 3 + 4, T2a-b), and (3) unfavourable IR (UIR; GS 4 + 3 or T2c). Biochemical relapse-free survival (BRFS), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) were assessed. RESULTS A total of 1754 patients from the RECAP database were included and stratified by risk group: FIR, n = 781 (44.5%); MIR, n = 252 (14.4%); and UIR, n = 721 (41.1%). Mean age was 71 years (range 47-86). Mean PSA was 10.4 ng/ml (range 6-20). The median radiotherapy dose was 74 Gy, with mean doses of 72.5 Gy (FIR), 73.4 Gy (MIR), and 72.8 Gy (UIR). Most patients (88%) received ADT for a median of 7.1 months. By risk group (FIR, MIR, UIR), ADT rates were, respectively, 88.9, 86.5, and 86.9%. Only patients with ≥ 24 months of follow-up post-EBRT were included in the survival analysis (n = 1294). At a median follow-up of 52 months (range 24-173), respective 5- and 10-year outcomes were: OS 93.6% and 79%; BRFS 88.9% and 71.4%; DFS 96.1% and 89%; CSS 98.9% and 94.6%. Complication rates (≥ grade 3) were: acute genitourinary (GU) 2%; late GU 1%; acute gastrointestinal (GI) 2%; late GI 1%. There was no significant association between risk group and BRFS or OS. However, patients with favourable-risk disease had significantly better 5- and 10-year DFS than patients with UIR: 98.7% vs. 92.4% and 92% vs. 85.8% (p = 0.0005). CSS was significantly higher (p = 0.0057) in the FIR group at 5 (99.7% vs. 97.3%) and 10 years (96.1% vs. 93.4%). On the multivariate analyses, the following were significant predictors of survival: ADT (BRFS and DFS); dose ≥ 74 Gy (BRFS); age (OS). CONCLUSIONS This is the first nationwide study in Spain to report long-term outcomes of patients with intermediate-risk PCa treated with EBRT. Survival outcomes were good, with a low incidence of both acute and late toxicity. Patients with unfavourable risk characteristics had significantly lower 5- and 10-year disease-free survival rates. ADT and radiotherapy dose ≥ 74 Gy were both significant predictors of treatment outcomes.
Collapse
Affiliation(s)
- A Hervás
- Department of Radiation Oncology, Hospital Ramón y Cajal, Madrid, Spain.
| | - J Pastor
- Department of Radiation Oncology, Hospital General de Valencia, Valencia, Spain
| | - C González
- Department of Radiation Oncology, Hospital Gregorio Marañón, Madrid, Spain
| | - J Jové
- Department of Radiation Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain
| | - A Gómez
- Department of Radiation Oncology, Hospital Clínico Universitario, Santiago de Compostela, Spain
| | - M Casaña
- Department of Radiation Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
| | - E Villafranca
- Department of Radiation Oncology, Hospital Clínico Universitario, Pamplona, Spain
| | - J L Mengual
- Department of Radiation Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
| | - V Muñoz
- Department of Radiation Oncology, Hospital do Mixoeiro, Vigo, Spain
| | - I Henriquez
- Department of Radiation Oncology, Hospital Universitario Sant Joan, Reus, Spain
| | - J Muñoz
- Department of Radiation Oncology, Hospital Infanta Cristina, Badajoz, Spain
| | - E Collado
- Department of Radiation Oncology, Hospital Uiversitario La Fe, Valencia, Spain
| | - J Clemente
- Department of Radiation Oncology, Instituto Valenciano de Oncologia, Alcoy, Spain
| |
Collapse
|
21
|
Lin S, Stoll B, Robinson J, Pastor J, Cruz S, Lau P, Marini J, Ipharraguerre I, Hartmann B, Holst J, Olutoye O, Fang Z, Burrin D. PSXI-33 Differential Action of TGR5 Agonists on GLP-2. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Lin
- Institute of Animal Nutrition, Sichuan Agricultural University,Chengdu, China (People’s Republic)
| | - B Stoll
- USDA-ARS Children’s Nutrition Research Center, Baylor College of Medicine,Houston, TX, United States
| | - J Robinson
- USDA-ARS Children’s Nutrition Research Center, Baylor College of Medicine,Houston, TX, United States
| | | | - S Cruz
- Texas Children’s Hospital, Division of Pediatric Surgery, Baylor College of Medicine,Houston, TX, United States
| | - P Lau
- Texas Children’s Hospital, Division of Pediatric Surgery, Baylor College of Medicine,Houston, TX, United States
| | - J Marini
- USDA-ARS Children’s Nutrition Research Center, Critical Care Medicine, Baylor College of Medicine,Houston, TX, United States
| | - I Ipharraguerre
- Institute of Human Nutrition and Food Science, University of Kiel,Kiel, Germany
| | - B Hartmann
- Department of Biomedical Sciences, and NNF Center for Basic Metabolic Research, University of Copenhagen,Copenhagen, Denmark
| | - J Holst
- Department of Biomedical Sciences, and NNF Center for Basic Metabolic Research, University of Copenhagen,Copenhagen, Denmark
| | - O Olutoye
- Texas Children’s Hospital, Division of Pediatric Surgery, Baylor College of Medicine,Houston, TX, United States
| | - Z Fang
- Institute of Animal Nutrition, Sichuan Agricultural University, Ya’an, China
| | - D Burrin
- USDA-ARS Children’s Nutrition Research Center, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine,Houston, TX, United States
| |
Collapse
|
22
|
Meléndez-Lazo A, Ordeix L, Planellas M, Pastor J, Solano-Gallego L. Clinicopathological findings in sick dogs naturally infected with Leishmania infantum : Comparison of five different clinical classification systems. Res Vet Sci 2018; 117:18-27. [DOI: 10.1016/j.rvsc.2017.10.011] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Revised: 10/29/2017] [Accepted: 10/30/2017] [Indexed: 10/18/2022]
|
23
|
Torres CV, Lopez-Manzanares L, Navas-Garcia M, Pastor J, Vega-Zelaya L, Garcia-Pallero MA, Sola RG. [Bilateral two-stage implantation for deep brain stimulation in the treatment of bilateral idiopathic Parkinson's disease: clinical outcomes]. Rev Neurol 2018; 66:1-6. [PMID: 29251336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
AIMS Simultaneous bilateral implantation of electrodes in the subthalamic nucleus for idiopathic Parkinson's disease (IPD) is associated with long surgery time, language disorders and post-operative confusion. Moreover, there is evidence of ipsilateral improvement after stimulation of the subthalamic nucleus. In order to optimise perioperative management a prospective study is conducted with deep brain stimulation (DBS) in the subthalamic nucleus in two consecutive unilateral procedures. PATIENTS AND METHODS We conducted a prospective study of 41 patients with bilateral IPD, with DBS implantation in two unilateral surgical phases. Its clinical outcomes are analysed according to the Unified Parkinson's Disease Rating Scale (UPDRS), the Hoehn and Yahr, and the Schwab and England scales, together with their complications. RESULTS The mean age was 61 ± 7 years old, 23 males. Five patients (12%) did not undergo surgery of the contralateral subthalamic nucleus due to good control. The mean on the motor UPDRS and the Hoehn and Yahr in preoperative pharmacological off was 44 ± 14 and 3, respectively, and 19 ± 8 and 1.8 at six months' follow-up. The mean improvement on the Schwab and England scale in the pre-operative period and at six months was 39%. Two patients suffered post-operative confusion, and one of them had transient dysarthria. CONCLUSIONS Bilateral DBS in two unilateral stages was an effective option with few complications in our series of patients with IPD. 10% of the patients did not require contralateral electrodes. It would be necessary to conduct a randomised study in patients who underwent bilateral surgery in one and two stages in order to confirm these results.
Collapse
Affiliation(s)
- C V Torres
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | | | - M Navas-Garcia
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - J Pastor
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - L Vega-Zelaya
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | | | - R G Sola
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| |
Collapse
|
24
|
Lopez-Guadamillas E, Muñoz-Martin M, Martinez S, Pastor J, Fernandez-Marcos PJ, Serrano M. PI3Kα inhibition reduces obesity in mice. Aging (Albany NY) 2017; 8:2747-2753. [PMID: 27816049 PMCID: PMC5191867 DOI: 10.18632/aging.101075] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 10/18/2016] [Indexed: 12/15/2022]
Abstract
Partial inhibition of PI3K is one of the best-validated and evolutionary conserved manipulations to extend longevity. The best known health beneficial effects of reduced PI3K are related to metabolism and include increased energy expenditure, reduced nutrient storage, and protection from obesity. We have previously shown that a dual chemical inhibitor of the alpha and delta PI3K isoforms (CNIO-PI3Ki) reduces obesity in mice and monkeys, without evident toxic effects after long-term treatment. Here, we dissect the role of the alpha and delta PI3K isoforms by making use of selective inhibitors against PI3Kɑ (BYL-719 also known as alpelisib) or PI3Kδ (GS-9820 also known as acalisib). Treatment of mice with the above mentioned inhibitors indicated that BYL-719 increases energy expenditure in normal mice and efficiently reduces body weight in obese (ob/ob) mice, whereas these effects were not observed with GS-9820. Of note, the dose of BYL-719 required to reduce obesity was 10-times higher than the equivalent dose of CNIO-PI3Ki, which could suggest that simultaneous inhibition of PI3K alpha and delta is more beneficial than single inhibition of the alpha isoform. In summary, we conclude that inhibition of PI3Kɑ is sufficient to increase energy expenditure and reduce obesity, and suggest that concomitant PI3Kδ inhibition could play an auxiliary role.
Collapse
Affiliation(s)
- Elena Lopez-Guadamillas
- Tumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid E28029, Spain
| | - Maribel Muñoz-Martin
- Tumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid E28029, Spain
| | - Sonia Martinez
- Experimental Therapeutics Programme, Spanish National Cancer Research Center (CNIO), Madrid E28029, Spain
| | - Joaquin Pastor
- Experimental Therapeutics Programme, Spanish National Cancer Research Center (CNIO), Madrid E28029, Spain
| | - Pablo J Fernandez-Marcos
- Bioactive Products and Metabolic Syndrome Group, Madrid Institute of Advanced Studies (IMDEA) in Food, CEI UAM+CSIC, Madrid E28049, Spain
| | - Manuel Serrano
- Tumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid E28029, Spain
| |
Collapse
|
25
|
Méndez-Pertuz M, Martínez P, Blanco-Aparicio C, Gómez-Casero E, Belen García A, Martínez-Torrecuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA. Modulation of telomere protection by the PI3K/AKT pathway. Nat Commun 2017; 8:1278. [PMID: 29097657 PMCID: PMC5668434 DOI: 10.1038/s41467-017-01329-2] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 09/11/2017] [Indexed: 11/23/2022] Open
Abstract
Telomeres and the insulin/PI3K pathway are considered hallmarks of aging and cancer. Here, we describe a role for PI3K/AKT in the regulation of TRF1, an essential component of the shelterin complex. PI3K and AKT chemical inhibitors reduce TRF1 telomeric foci and lead to increased telomeric DNA damage and fragility. We identify the PI3Kα isoform as responsible for this TRF1 inhibition. TRF1 is phosphorylated at different residues by AKT and these modifications regulate TRF1 protein stability and TRF1 binding to telomeric DNA in vitro and are important for in vivo TRF1 telomere location and cell viability. Patient-derived breast cancer PDX mouse models that effectively respond to a PI3Kα specific inhibitor, BYL719, show decreased TRF1 levels and increased DNA damage. These findings functionally connect two of the major pathways for cancer and aging, telomeres and the PI3K pathway, and pinpoint PI3K and AKT as novel targets for chemical modulation of telomere protection. Regulation of telomeres and the insulin/PI3K pathway both have roles in aging and cancer development but have not been functionally linked. Here the authors demonstrate that PI3K, via downstream targets, regulates TRF1 via phosphorylation.
Collapse
Affiliation(s)
- Marinela Méndez-Pertuz
- Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Paula Martínez
- Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Carmen Blanco-Aparicio
- Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Elena Gómez-Casero
- Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Ana Belen García
- Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Jorge Martínez-Torrecuadrada
- Biotechnology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Marta Palafox
- Experimental Therapeutics Group, Vall d´Hebron Institute of Oncology (VHIO), Natzaret 115-117, Barcelona, E-08035, Spain
| | - Javier Cortés
- Experimental Therapeutics Group, Vall d´Hebron Institute of Oncology (VHIO), Natzaret 115-117, Barcelona, E-08035, Spain
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d´Hebron Institute of Oncology (VHIO), Natzaret 115-117, Barcelona, E-08035, Spain
| | - Joaquin Pastor
- Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain
| | - Maria A Blasco
- Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain.
| |
Collapse
|
26
|
Vega-Zelaya L, Torres CV, Navas-Garcia M, Sola RG, Pastor J. [New thalamic potential associated with somatosensory evoked potentials]. Rev Neurol 2017; 65:322-326. [PMID: 28929474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION The response of the thalamus during the study with somatosensory evoked potentials (SSEP) is not sufficiently understood. CASE REPORT A 17-year-old man undergoing surgery for deep brain stimulation in the centromedian nucleus for drug-resistant epilepsy under complete sedation. During the intervention, the responses to SSEPs of the thalamic nuclei were recorded by means of four microelectrodes. These responses can be decomposed into three types: local field potentials (LFP), low amplitude fast oscillations (LFO), and high amplitude slow oscillations (HSO). LFO are widespread in much of the registered regions. However, HSOs are located at a single point in the registry and are closely associated with LFPs. CONCLUSIONS Although the presence of LFO has been considered as an indicator of the presence of the sensory thalamus, its wide extension by different thalamic nuclei suggests that it is an unspecific response to SSEPs. However, the restricted spatial location of HSO and their association with LFP suggest that these newly described potentials are the markers for the presence of the sensory thalamus. Their identification may prove very useful in thalamic deep brain stimulation either in awake patients or especially in those requiring sedation.
Collapse
Affiliation(s)
- L Vega-Zelaya
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - C V Torres
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - M Navas-Garcia
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - R G Sola
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - J Pastor
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| |
Collapse
|
27
|
Hervás A, Gómez-Caamaño A, Casaña M, Gómez-Iturriaga A, Pastor J, Jove J, Mengual JL, Gónzalez-San Segundo C, Muñoz J. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database. Clin Transl Oncol 2017; 20:193-200. [PMID: 28667448 DOI: 10.1007/s12094-017-1709-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Accepted: 06/20/2017] [Indexed: 12/20/2022]
Abstract
PURPOSE To compare adjuvant radiotherapy (ART) to salvage radiotherapy (SRT) after radical prostatectomy (RP) in a cohort of prostate cancer (PCa) patients. The primary aim was to comparatively assess 2- and 5-year biochemical relapse-free survival (BRFS). A secondary aim was to identify predictors of survival. PATIENTS AND METHODS Data were acquired from the RECAP database, a population-based prostate cancer registry in Spain. Inclusion criteria included RP (with or without lymphadenectomy) followed by ART or SRT. A total of 702 patients were analyzed. Pre-RT PSA values (>0.5 vs. ≤0.5 ng/ml), pathological stage (T1-2 vs. T3-4), post-surgical Gleason score (≤7 vs. 8-10), margin status (positive vs. negative), hormonal treatment (yes vs. no), and RT dose (≤66 Gy vs. >66 Gy) were evaluated to assess their impact on BRFS. RESULTS The mean patient age in the ART and SRT groups, respectively, was 64 years (range 42-82) and 64.8 years (range 42-82). Median follow-up after RT in the whole sample was 34 months (range 3-141). A total of 702 patients were included: 223 (31.8%) received ART and 479 (68.2%) SRT. BRFS rates (95% CI) in the ART and SRT groups at months 24 and 60 were, respectively: 98.1% (95.9-100.0%) vs. 91.2% (88.2-94.2%) and 84.5% (76.4-92.6%) vs. 74.0% (67.4-80.7%) (p = 0.004). No significant differences in OS were observed (p = 0.053). The following variables were significant predictors of biochemical recurrence in the SRT group: (1) positive surgical margin status (p = 0.049); (2) no hormonotherapy (p = 0.03); (3) total prostate dose ≤66 Gy (p = 0.004); and pre-RT PSA ≥0.5 ng/ml (p = 0.013). CONCLUSIONS This is the first nationwide study in Spain to evaluate a large cohort of PCa patients treated with RP followed by postoperative RT. ART yielded better 2- and 5-year BRFS rates, although OS was equivalent. These findings are consistent with most other published studies and support ART in patients with adverse prognostic characteristics after radical prostatectomy. Prospective trials are needed to compare immediate ART to early SRT to better determine their relative benefits.
Collapse
Affiliation(s)
- A Hervás
- Department of Radiation Oncology, Hospital Ramón Y Cajal, Madrid, Spain.
| | - A Gómez-Caamaño
- Department of Radiation Oncology, Hospital Clínico Universitario, Santiago de Compostela, Spain
| | - M Casaña
- Department of Radiation Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
| | - A Gómez-Iturriaga
- Department of Radiation Oncology, Hospital Universitario Cruces, Barakaldo, Spain
| | - J Pastor
- Department of Radiation Oncology, Hospital General de Valencia, Valencia, Spain
| | - J Jove
- Department of Radiation Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain
| | - J L Mengual
- Department of Radiation Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
| | | | - J Muñoz
- Department of Radiation Oncology, Hospital Infanta Cristina, Badajoz, Spain
| |
Collapse
|
28
|
Mosteiro L, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, Rovira M, Fernandez-Marcos PJ, Muñoz-Martin M, Blanco-Aparicio C, Pastor J, Gómez-López G, De Martino A, Blasco MA, Abad M, Serrano M. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 2017; 354:354/6315/aaf4445. [PMID: 27884981 DOI: 10.1126/science.aaf4445] [Citation(s) in RCA: 389] [Impact Index Per Article: 55.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 07/01/2016] [Accepted: 10/06/2016] [Indexed: 12/11/2022]
Abstract
Reprogramming of differentiated cells into pluripotent cells can occur in vivo, but the mechanisms involved remain to be elucidated. Senescence is a cellular response to damage, characterized by abundant production of cytokines and other secreted factors that, together with the recruitment of inflammatory cells, result in tissue remodeling. Here, we show that in vivo expression of the reprogramming factors OCT4, SOX2, KLF4, and cMYC (OSKM) in mice leads to senescence and reprogramming, both coexisting in close proximity. Genetic and pharmacological analyses indicate that OSKM-induced senescence requires the Ink4a/Arf locus and, through the production of the cytokine interleukin-6, creates a permissive tissue environment for in vivo reprogramming. Biological conditions linked to senescence, such as tissue injury or aging, favor in vivo reprogramming by OSKM. These observations may be relevant for tissue repair.
Collapse
Affiliation(s)
- Lluc Mosteiro
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain
| | - Cristina Pantoja
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain
| | - Noelia Alcazar
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain
| | - Rosa M Marión
- Telomeres and Telomerase Group, CNIO, Madrid E28029, Spain
| | - Dafni Chondronasiou
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain
| | - Miguel Rovira
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain
| | - Pablo J Fernandez-Marcos
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.,Laboratory of Bioactive Products and Metabolic Syndrome, Madrid Institute for Advanced Studies (IMDEA) in Food, CEI UAM+CSIC, Madrid E28049, Spain
| | - Maribel Muñoz-Martin
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain
| | | | - Joaquin Pastor
- Experimental Therapeutics Programme, CNIO, Madrid E28029, Spain
| | | | | | - Maria A Blasco
- Telomeres and Telomerase Group, CNIO, Madrid E28029, Spain
| | - María Abad
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.,Cell Plasticity and Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona E08035, Spain
| | - Manuel Serrano
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
| |
Collapse
|
29
|
Sanz-Garcia A, Vega-Zelaya L, Pastor J, Sola RG, Ortega GJ. [When does post-ictal period start in temporal lobe epilepsy? A quantitative EEG perspective]. Rev Neurol 2017; 64:337-346. [PMID: 28368080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION In partial seizures, from a clinical point of view or even from electroencephalography characterization of post-ictal period can be difficult. The spectral and complex network analysis could lead to a more accurate definition of its limits, as well as to a great understanding of the seizures. PATIENTS AND METHODS Digital EEG recordings from scalp and foramen oval electrodes were used, 32 seizures, from 15 patients with drug-resistant mesial temporal lobe epilepsy (Engel I). We analyzed numerically: the spectral entropy, the different frequency bands and several variables used to characterize the cortical network, density of links, modularity, cluster coefficient and average path length. Variations of for post-ictal versus pre-ictal periods were quantified. RESULTS The cortical network density of links increased during the post-ictal period of complex seizures matching with an spectral entropy decrease, mainly due to an increase in Delta band activity. This variables reached extreme values around one minute after seizure end, defined by classical electroencephalography. CONCLUSIONS Our results can be explained by the appearance of an 'ending' mechanism that starts in the ictal period, classically defined, and reach their maximum effect during the post-ictal period. These results could be useful to define the post-ictal period start, as the moment with maximum synchrony, which has a highest density of links and a lowest spectral entropy.
Collapse
Affiliation(s)
- A Sanz-Garcia
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - L Vega-Zelaya
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - J Pastor
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - R G Sola
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - G J Ortega
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| |
Collapse
|
30
|
Vilalta L, Meléndez-Lazo A, Doria G, Ramis A, Solano-Gallego L, Pastor J, Martorell J. Clinical, Cytological, Histological and Immunohistochemical Features of Cutaneous Mast Cell Tumours in Ferrets ( Mustela putorius furo ). J Comp Pathol 2016; 155:346-355. [DOI: 10.1016/j.jcpa.2016.07.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 07/22/2016] [Accepted: 07/27/2016] [Indexed: 10/21/2022]
|
31
|
Blanco Aparicio C, Renner O, Gomez-Casero E, Albarran MI, Cebria A, Barrera B, Aguirre E, Rodriguez de Miguel MDC, Urbano M, Hernandez AI, Gomez de la Oliva C, Rivero V, Riesco RC, Martinez Gonzalez S, Pastor J. Abstract 4337: Novel potent and selective orally available CDK8/19 kinase inhibitors. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CDK8 and its paralog CDK19 are cyclin-dependent kinases and together with CDK7 and CDK9 belongs to the group of C-terminal domain (CTD) kinases that phosphorylate the CTD of RNA polymerase II, thus regulating transcription. CDK8 together with its partner Cyclin C, MED12 and MED13 are components of multi-protein Mediator complex which couples action of transcription factors with the molecular machinery that carries out transcription, e.g. CDK8 couple basal transcriptional machinery to sequence-specific transcription factors such as Notch, p53, β-catenin, and also repress the transcription of other genes. As Mediator independent roles, CDK8 has been shown to act as part of a separate complex behaving as a histone kinase. Moreover, CDK8 has been identified as a major kinase in the response to IFN signaling mediated STAT1-S727 phosphorylation.
Several studies indicated that high overexpression and activity of CDK8 could be a driver of malignant progression in colorectal cancer being a marker of poor prognosis. Moreover, in gastric cancer CDK8 expression and the delocalization of β-catenin expression showed a significant positive correlation with carcinogenesis and tumor progression, especially lymph node metastasis. Recently, gene amplification of CDK8, CDK19, CCNC and MED13 in breast cancers has been related with poor response to adjuvant therapy. These results suggest that CDK8 inhibitors may become a unique class of anticancer drugs that could increase the efficacy of cancer therapy by blocking chemotherapy-induced production of tumor-promoting secreted factors.
We have carried out a medium throughput screening campaign which led to the discovery of several low nanomolar hits belonging to 3 different chemical series. Later on, we have performed a Hit Generation phase, designing novel inhibitors within a patentable chemical space. Here, we have taken into account information from the chemical structures of the screening hits, X-ray structure of CDK8 protein co-crystalized with sorafenib, docking studies, chemical feasibility and intellectual property.
We have identified a novel chemical series of CDK8/19 inhibitors. After a HtL exploration we have reached lead compounds with potency in the picomolar range and high selectivity versus a panel of 468 protein kinases. The leads display cellular activity by blocking β−catenin reporter activity and STAT1 phoshorylation in the low nanomolar range. Lead compounds have been screened in a panel of tumoral cell lines, showing a defined profile in terms of sensitivity with GI50s which range from nanomolar to low micromolar values. These inhibitors induce cell death in a dose response manner. The novel chemical series show a drug-like profile in terms of solubility, permeability, CYP450 inhibition and hERG. The identified lead compounds are orally bioavailable, with good clearance, volume of distribution and exposure levels. A selected lead compound has been used in in vivo PK-PD studies showing positive results.
Citation Format: Carmen Blanco Aparicio, Oliver Renner, Elena Gomez-Casero, Maria Isabel Albarran, Antonio Cebria, Borja Barrera, Enara Aguirre, Maria del Carmen Rodriguez de Miguel, Manuel Urbano, Ana Isabel Hernandez, Cristina Gomez de la Oliva, Virginia Rivero, Rosario Concepcion Riesco, Sonia Martinez Gonzalez, Joaquin Pastor. Novel potent and selective orally available CDK8/19 kinase inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4337.
Collapse
|
32
|
Silvestrini P, Batchelor D, Allenspach K, Maunder C, Seth M, Mas A, Hill T, Serrano G, Roura X, Planellas M, German AJ, Pastor J. Clinical leishmaniasis in dogs living in the UK. J Small Anim Pract 2016; 57:453-8. [PMID: 27251904 DOI: 10.1111/jsap.12503] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Revised: 03/15/2016] [Accepted: 03/18/2016] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To investigate the prevalence of leishmaniasis in dogs in the UK and to describe clinical presentation, clinicopathological abnormalities, therapeutic protocols and outcome in this non-endemic country. MATERIALS AND METHODS Medical records of dogs diagnosed with leishmaniasis at seven referral centres in the UK were retrospectively reviewed. RESULTS The prevalence was between 0·007 and 0·04% with a higher number of cases in southern England. All dogs had a history of travel to or from an endemic country. Lethargy, dermatological disease, decreased appetite and lameness were the most common reasons for presentation. Allopurinol was used alone for treatment in the majority of cases. CLINICAL SIGNIFICANCE Although rare, leishmaniasis should be considered in dogs in the UK if they have compatible clinical signs and history of travel to or from endemic areas.
Collapse
Affiliation(s)
- P Silvestrini
- Department of Small Animal Internal Medicine, School of Veterinary Science, University of Liverpool, Neston CH64 7TE
| | - D Batchelor
- Department of Small Animal Internal Medicine, School of Veterinary Science, University of Liverpool, Neston CH64 7TE
| | - K Allenspach
- Department of Veterinary Clinical Services, Royal Veterinary College of London, North Mymms, Herts NW1 0TU
| | - C Maunder
- Department of Small Animal Medicine, University of Bristol, Bristol, North Somerset BS40 5DU
| | - M Seth
- Department of Small Animal Internal Medicine, Animal Health Trust, Newmarket, Suffolk CB8 7UU
| | - A Mas
- Anderson Moores Veterinary Specialists Ltd, Winchester SO212LL
| | - T Hill
- Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG
| | - G Serrano
- Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES
| | - X Roura
- Hospital Clinic Veterinari, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain
| | - M Planellas
- Hospital Clinic Veterinari, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain
| | - A J German
- Department of Small Animal Internal Medicine, School of Veterinary Science, University of Liverpool, Neston CH64 7TE
| | - J Pastor
- Hospital Clinic Veterinari, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain
| |
Collapse
|
33
|
Torres M, Pastor J, Roura X, Tabar MD, Espada Y, Font A, Balasch J, Planellas M. Adverse urinary effects of allopurinol in dogs with leishmaniasis. J Small Anim Pract 2016; 57:299-304. [DOI: 10.1111/jsap.12484] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 12/23/2015] [Accepted: 02/18/2016] [Indexed: 01/07/2023]
Affiliation(s)
- M. Torres
- Servei d'Urgències i Medecina Interna, Hospital Veterinari Balmes; Carrer Balmes 81 08008 Barcelona Spain
| | - J. Pastor
- Hospital Clínic Veterinari and Animal Medicine and Surgery Department, Faculty of Veterinary Medicine; Universitat Autònoma de Barcelona; Campus de la UAB, Plaza Cívica 08193 Bellaterra Spain
| | - X. Roura
- Hospital Clínic Veterinari and Animal Medicine and Surgery Department, Faculty of Veterinary Medicine; Universitat Autònoma de Barcelona; Campus de la UAB, Plaza Cívica 08193 Bellaterra Spain
| | - M. D. Tabar
- Servicio de Medicina Interna, Centro Policlínico Veterinario Raspeig, Calle Veterinario Manuel Isidro Rodríguez Rodriguez; 17, 03690, San Vicente del Raspeig Alicante Spain
| | - Y. Espada
- Hospital Clínic Veterinari and Animal Medicine and Surgery Department, Faculty of Veterinary Medicine; Universitat Autònoma de Barcelona; Campus de la UAB, Plaza Cívica 08193 Bellaterra Spain
| | - A. Font
- Servei de Medecina Interna, Hospital Ars Veterinària; Carrer Cardedeu 3 08023 Barcelona Spain
| | - J. Balasch
- Servei d'Urgències i Medecina Interna, Hospital Veterinari Balmes; Carrer Balmes 81 08008 Barcelona Spain
| | - M. Planellas
- Hospital Clínic Veterinari and Animal Medicine and Surgery Department, Faculty of Veterinary Medicine; Universitat Autònoma de Barcelona; Campus de la UAB, Plaza Cívica 08193 Bellaterra Spain
| |
Collapse
|
34
|
Aragoneses-Fenoll L, Montes-Casado M, Ojeda G, Acosta YY, Herranz J, Martínez S, Blanco-Aparicio C, Criado G, Pastor J, Dianzani U, Portolés P, Rojo JM. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol 2016; 106:56-69. [PMID: 26883061 DOI: 10.1016/j.bcp.2016.02.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Accepted: 02/11/2016] [Indexed: 11/29/2022]
Abstract
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110α and p110δ class IA PI3K. Whereas the functioning of PI3K p110δ in immune and autoimmune reactions is well established, the role of p110α is less well understood. Here, a novel dual p110α/δ inhibitor (ETP-46321) and highly specific p110α (A66) or p110δ (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4(+) T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110δ inhibitor than by the p110α inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-γ), T-bet expression and NFAT activation. In activated CD4(+) T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-γ better than A66. The p110α/δ inhibitor ETP-46321, or p110α plus p110δ inhibitors also inhibited IL-21 secretion by differentiated CD4(+) T follicular (Tfh) or IL-17-producing (Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-γ, or clinical symptoms. Hence, p110α as well as p110δ Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis.
Collapse
Affiliation(s)
- L Aragoneses-Fenoll
- Unidad de Inmunología Celular, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | - M Montes-Casado
- Unidad de Inmunología Celular, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | - G Ojeda
- Unidad de Inmunología Celular, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | - Y Y Acosta
- Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain
| | - J Herranz
- Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain
| | - S Martínez
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Spain
| | - C Blanco-Aparicio
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Spain
| | - G Criado
- Hospital 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (I+12), E-28041 Madrid, Spain
| | - J Pastor
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Spain
| | - U Dianzani
- Interdisciplinary Research Center of Autoimmune Diseases (IRCAD) and Department of Health Sciences, University of Piemonte Orientale (UPO), Novara, Italy
| | - P Portolés
- Unidad de Inmunología Celular, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
| | - J M Rojo
- Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
| |
Collapse
|
35
|
Menachem A, Bodner O, Pastor J, Raz A, Kloog Y. Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors. Cell Death Discov 2015; 1:15047. [PMID: 27551476 PMCID: PMC4979473 DOI: 10.1038/cddiscovery.2015.47] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2015] [Revised: 09/02/2015] [Accepted: 09/08/2015] [Indexed: 12/13/2022] Open
Abstract
Anaplastic Thyroid carcinoma is an extremely aggressive solid tumor that resists most treatments and is almost always fatal. Galectin-3 (Gal-3) is an important marker for thyroid carcinomas and a scaffold of the K-Ras protein. S-trans, transfarnesylthiosalicylic acid (FTS; Salirasib) is a Ras inhibitor that inhibits the active forms of Ras proteins. Modified citrus pectin (MCP) is a water-soluble citrus-fruit-derived polysaccharide fiber that specifically inhibits Gal-3. The aim of this study was to develop a novel drug combination designed to treat aggressive anaplastic thyroid carcinoma. Combined treatment with FTS and MCP inhibited anaplastic thyroid cells proliferation in vitro by inducing cell cycle arrest and increasing apoptosis rate. Immunoblot analysis revealed a significant decrease in Pan-Ras, K-Ras, Ras-GTP, p-ERK, p53, and Gal-3 expression levels and significant increase in p21 expression levels. In nude mice, treatment with FTS and MCP inhibited tumor growth. Levels of Gal-3, K-Ras-GTP, and p-ERK were significantly decreased. To conclude, our results suggest K-Ras and Gal-3 as potential targets in anaplastic thyroid tumors and herald a novel treatment for highly aggressive anaplastic thyroid carcinoma.
Collapse
Affiliation(s)
- A Menachem
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University , Tel Aviv, Israel
| | - O Bodner
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University , Tel Aviv, Israel
| | - J Pastor
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University , Tel Aviv, Israel
| | - A Raz
- The Departments of Oncology and Pathology, School of Medicine, The Karmanos Cancer Institute, Wayne State University , Detroit, MI, USA
| | - Y Kloog
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University , Tel Aviv, Israel
| |
Collapse
|
36
|
Torres CV, Pastor J, Garcia-Navarrete E, Pulido-Rivas P, Sola RG. Classification of structural lesions in magnetic resonance imaging. Surgical implications in drug-resistant epilepsy patients. Rev Neurol 2015; 61:241-248. [PMID: 26350774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION The presence of a structural lesion in the preoperative magnetic resonance imaging (MRI) of drug-resistant epilepsy patients has been usually associated with a favourable surgical outcome. We present our experience in our Epilepsy Surgery Unit. PATIENTS AND METHODS Clinical records from 265 patients, operated on from 1990-2010 in our institution, were reviewed. Patients were classified, according to MRI findings, into three groups: surgical lesion (SL), tumors or vascular malformations requiring surgery 'per se'; orientative lesion (OL), dysplasia, atrophy or mesial temporal sclerosis; and (NL) group, with normal MRI. Seizure outcomes were analysed in relation to this classification. RESULTS Period 1990-2000, 151 patients: 87% of SL, 65% of OL and 57% of NL patients were in Engel class I or II at the two-year follow-up. Among temporal lobe epilepsy cases (TLE), 87% of SL, 67% of OL and 56% of NL patients achieved seizure control. Differences were statistically significative. Period 2001-2010, 114 patients: 100% of SL, 90% of OL, and 81% of NL patients were in Engel's class I or II. Both TLE and extratemporal (ETLE) SL patients obtained a 100% seizure control. Among the OL patients, 95% with TLE and 43% of ETLE achieved seizure control. In the NL group, the percentages were 88% in TLE, and 50% in ETLE. CONCLUSIONS In our series, SL was a predictor of a favorable outcome. In TLE patients, good results were achieved despite normal MRI. Patients with ETLE and NL did not have a worse outcome than those with OL. A classification in SL, OL and NL seems more helpful for predicting the surgical outcome than the traditional classification lesion versus non-lesion MRI. Radiological findings must be carefully evaluated in the context of a complete epilepsy surgery evaluation.
Collapse
Affiliation(s)
- C V Torres
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | | | | | | | | |
Collapse
|
37
|
Cassoudesalle H, Scannella S, Pariente J, Lotterie J, Celsis P, Castel-Lacanal E, Marque P, De Boissezon X, Pastor J. The behavioral and electrophysiological effects of posterior parietal cortex damage in spatial audio-visual conflict. Ann Phys Rehabil Med 2015. [DOI: 10.1016/j.rehab.2015.07.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
38
|
Rüb J, Rehmann R, von Landenberg N, Roghmann F, Stude P, Tegenthoff M, Noldus J, Pastor J. [Segmental testicular infarction. Unusual complication of intravenous immunoglobulin therapy for multifocal motor neuropathy]. Urologe A 2015; 54:1421-4. [PMID: 26303740 DOI: 10.1007/s00120-015-3941-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
We describe the previously unknown case of segmental testicular infarction as an iatrogenic complication of intravenous immunoglobulin administration in a patient with multifocal motor neuropathy.
Collapse
Affiliation(s)
- J Rüb
- Klinik für Urologie und Neurourologie, Marien-Hospital Herne, Ruhr-Universität Bochum, Widumer Straße 8, 44627, Herne, Deutschland.
| | - R Rehmann
- Neurologische Klinik, Ruhr-Universität Bochum, BG-Universitätsklinikum Bergmannsheil Bochum, Bochum, Deutschland
| | - N von Landenberg
- Klinik für Urologie und Neurourologie, Marien-Hospital Herne, Ruhr-Universität Bochum, Widumer Straße 8, 44627, Herne, Deutschland
| | - F Roghmann
- Klinik für Urologie und Neurourologie, Marien-Hospital Herne, Ruhr-Universität Bochum, Widumer Straße 8, 44627, Herne, Deutschland
| | - P Stude
- Neurologische Klinik, Ruhr-Universität Bochum, BG-Universitätsklinikum Bergmannsheil Bochum, Bochum, Deutschland
| | - M Tegenthoff
- Neurologische Klinik, Ruhr-Universität Bochum, BG-Universitätsklinikum Bergmannsheil Bochum, Bochum, Deutschland
| | - J Noldus
- Klinik für Urologie und Neurourologie, Marien-Hospital Herne, Ruhr-Universität Bochum, Widumer Straße 8, 44627, Herne, Deutschland
| | - J Pastor
- Klinik für Urologie und Neurourologie, Marien-Hospital Herne, Ruhr-Universität Bochum, Widumer Straße 8, 44627, Herne, Deutschland
| |
Collapse
|
39
|
Pastor J, Pádr R. [Using a stent graft in the treatment of hepatic artery bleeding after pancreatoduodenectomy]. Rozhl Chir 2015; 94:256-260. [PMID: 26174346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Delayed bleeding is a potential complication of pancreatoduodenectomy. Its treatment is either endovascular or surgical (stentgraft, embolization). Our case report presents a patient with bleeding from the hepatic artery pseudoaneurysm within a period of 3 months after pancreatoduodenectomy for common bile duct carcinoma, resolved using a stent graft.
Collapse
|
40
|
Ortega-Molina A, Lopez-Guadamillas E, Mattison JA, Mitchell SJ, Muñoz-Martin M, Iglesias G, Gutierrez VM, Vaughan KL, Szarowicz MD, González-García I, López M, Cebrián D, Martinez S, Pastor J, de Cabo R, Serrano M. Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys. Cell Metab 2015; 21:558-70. [PMID: 25817535 PMCID: PMC5867518 DOI: 10.1016/j.cmet.2015.02.017] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Revised: 01/30/2015] [Accepted: 02/19/2015] [Indexed: 01/12/2023]
Abstract
Genetic inhibition of PI3K signaling increases energy expenditure, protects from obesity and metabolic syndrome, and extends longevity. Here, we show that two pharmacological inhibitors of PI3K, CNIO-PI3Ki and GDC-0941, decrease the adiposity of obese mice without affecting their lean mass. Long-term treatment of obese mice with low doses of CNIO-PI3Ki reduces body weight until reaching a balance that is stable for months as long as the treatment continues. CNIO-PI3Ki treatment also ameliorates liver steatosis and decreases glucose serum levels. The above observations have been recapitulated in independent laboratories and using different oral formulations of CNIO-PI3Ki. Finally, daily oral treatment of obese rhesus monkeys for 3 months with low doses of CNIO-PI3Ki decreased their adiposity and lowered their serum glucose levels, in the absence of detectable toxicities. Therefore, pharmacological inhibition of PI3K is an effective and safe anti-obesity intervention that could reverse the negative effects of metabolic syndrome in humans.
Collapse
Affiliation(s)
- Ana Ortega-Molina
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Elena Lopez-Guadamillas
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Julie A Mattison
- Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - Sarah J Mitchell
- Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - Maribel Muñoz-Martin
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Gema Iglesias
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Vincent M Gutierrez
- Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - Kelli L Vaughan
- Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA; SoBran, Inc., Burtonsville, MD 20866, USA
| | - Mark D Szarowicz
- Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA; SoBran, Inc., Burtonsville, MD 20866, USA
| | - Ismael González-García
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15782, Spain
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15782, Spain
| | - David Cebrián
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Sonia Martinez
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Joaquin Pastor
- Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Rafael de Cabo
- Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - Manuel Serrano
- Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
| |
Collapse
|
41
|
Tvarijonaviciute A, García-Martínez JD, Caldin M, Martínez-Subiela S, Tecles F, Pastor J, Ceron JJ. Serum paraoxonase 1 (PON1) activity in acute pancreatitis of dogs. J Small Anim Pract 2014; 56:67-71. [DOI: 10.1111/jsap.12297] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2014] [Revised: 09/04/2014] [Accepted: 09/22/2014] [Indexed: 12/22/2022]
Affiliation(s)
- A. Tvarijonaviciute
- Departament de Medicina i Cirurgia Animals; Universitat Autònoma de Barcelona; 08193 Bellaterra Barcelona Spain
| | - J. D. García-Martínez
- Interdisciplinary Laboratory of Clinical Pathology, Iterlab-UMU, Campus of Excellence Mare Nostrum; University of Murcia; 30100 Espinardo Murcia Spain
| | - M. Caldin
- San Marco Veterinary Hospital; 35141 Padova Italy
| | - S. Martínez-Subiela
- Interdisciplinary Laboratory of Clinical Pathology, Iterlab-UMU, Campus of Excellence Mare Nostrum; University of Murcia; 30100 Espinardo Murcia Spain
| | - F. Tecles
- Interdisciplinary Laboratory of Clinical Pathology, Iterlab-UMU, Campus of Excellence Mare Nostrum; University of Murcia; 30100 Espinardo Murcia Spain
| | - J. Pastor
- Departament de Medicina i Cirurgia Animals; Universitat Autònoma de Barcelona; 08193 Bellaterra Barcelona Spain
| | - J. J. Ceron
- Interdisciplinary Laboratory of Clinical Pathology, Iterlab-UMU, Campus of Excellence Mare Nostrum; University of Murcia; 30100 Espinardo Murcia Spain
| |
Collapse
|
42
|
Aguirre E, Renner O, de Miguel MR, Albarran M, Cebria A, Cebrian D, Ramos-Lima F, Pastor J, Blanco-Aparicio C. 198 Genetic and pharmacological inhibition of PIM-1 reduces tumor development in a K-Ras-driven mouse model of non-small cell lung cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70324-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
Gutiérrez-Ginés MJ, Hernández AJ, Pérez-Leblic MI, Pastor J, Vangronsveld J. Phytoremediation of soils co-contaminated by organic compounds and heavy metals: bioassays with Lupinus luteus L. and associated endophytic bacteria. J Environ Manage 2014; 143:197-207. [PMID: 24912107 DOI: 10.1016/j.jenvman.2014.04.028] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 03/10/2014] [Accepted: 04/23/2014] [Indexed: 06/03/2023]
Abstract
In the central part of the Iberian Peninsula there are old sealed landfills containing soils co-contaminated by several heavy metals (Cu, Zn, Pb, Cd, Ni, As, Cr, Fe, Al, Mn) and organic pollutants of different families (hydrocarbons, polycyclic aromatic hydrocarbons, polychlorinated biphenyls, pesticides and other organochlorinated compounds, phenols and volatile compounds), which this work will address. We have focused on phytoremedial plants that are able to deal with this type of complex pollution, not only species that tolerate the joint effect of heavy metals in the soil, but also those that can take advantage of associated bacteria to efficiently break down organic compounds. This study was carried out with Lupinus luteus and its endophytes in two greenhouse experiments: A) growing in a substrate artificially contaminated with benzo(a)pyrene (BaP), and B) using real co-contaminated landfill soils. Endophytes of roots and shoots were isolated in both bioassays. Plant growth-promotion tests and organic pollutant tolerance and degradation tests were conducted on all strains isolated in bioassay A), and on those proving to be pure cultures from bioassay B). The selected landfill is described as are isolation and test procedures. Results indicate that plants did not show toxicity symptoms when exposed to BaP but did when grown in landfill soil. Some endophytes demonstrated plant growth-promotion capacity and tolerance to BaP and other organic compounds (diesel and PCB commercial mixtures). A few strains may even have the capacity to metabolize those organic pollutants. The overall decline in plant growth-promotion capacity in those strains isolated from the landfill soil experiment, compared with those from the bioassay with BaP, may indicate that lupin endophytes are not adapted to metal concentration in roots and shoots and fail to grow. As a result, most isolated root endophytes must have colonized root tissues from the soil. While preliminary degradation tests showed promising results (some strains exhibiting the potential to use organic pollutants as their sole source of carbon), these are not conclusive and further in-depth degradation assays need to be performed.
Collapse
Affiliation(s)
| | - A J Hernández
- Department of Life Sciences, Alcalá University, Alcalá de Henares, Spain
| | - M I Pérez-Leblic
- Department of Biomedical Sciences, Alcalá University, Alcalá de Henares, Spain
| | - J Pastor
- Department of Environmental Biology, Natural Sciences National Museum, CSIC, Madrid, Spain
| | - J Vangronsveld
- Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium
| |
Collapse
|
44
|
Monzote L, Pastor J, Scull R, Gille L. Antileishmanial activity of essential oil from Chenopodium ambrosioides and its main components against experimental cutaneous leishmaniasis in BALB/c mice. Phytomedicine 2014; 21:1048-1052. [PMID: 24768411 DOI: 10.1016/j.phymed.2014.03.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Revised: 01/23/2014] [Accepted: 03/02/2014] [Indexed: 06/03/2023]
Abstract
UNLABELLED Chenopodium ambrosioides have been used during centuries by native people to treat parasitic diseases. AIMS OF THE STUDY To compare the in vivo anti-leishmanial activity of the essential oil (EO) from C. ambrosioides and its major components (ascaridole, carvacrol and caryophyllene oxide). MATERIALS AND METHODS Anti-leishmanial effect was evaluated in BALB/c mice infected with Leishmania amazonensis and treated with the EO, main compounds and artificial mix of pure components by intralesional route at 30 mg/kg every 4 days during 14 days. Diseases progression and parasite burden in infected tissues were determined. RESULTS EO prevented lesion development compared (p<0.05) with untreated animals and treated with vehicle. In addition, the efficacy of EO was also statistically superior (p<0.05) compared with the glucantime-treated animals. No potential effects were observed with pure components treatment. Mix of pure compounds cause death of animals after 3 days of treatment. CONCLUSIONS Our results demonstrate the superiority of EO against experimental cutaneous leishmaniasis caused by L. amazonensis.
Collapse
Affiliation(s)
- L Monzote
- Parasitology Department, Institute of Tropical Medicine "Pedro Kouri", Havana, Cuba.
| | - J Pastor
- Parasitology Department, Institute of Tropical Medicine "Pedro Kouri", Havana, Cuba
| | - R Scull
- Department of Chemistry, Institute of Pharmacy and Food, Havana University, Cuba
| | - L Gille
- Biochemical Pharmacology and Toxicology Unit, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
45
|
Pastor J, Adámek S, Polanecký O. [Primary small bowel volvulus in a young adult]. Rozhl Chir 2014; 93:322-324. [PMID: 25047972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The authors present a rare case of a young male patient with primary small bowel volvulus. They show the main points to be considered in clinical diagnosis of this kind of acute abdomen and the importance of CT scan in such cases.
Collapse
|
46
|
Blanco Aparicio C, Renner O, Gomez-Casero E, Cebriá A, Ajenjo N, Aguirre E, Cebrián D, Rodriguez de Miguel MC, Pequeño B, Albarrán M, Riesco R, García AB, Alvarez R, O'Neill M, Martinez S, Pastor J. Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-a275] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. The redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape to targeted therapies. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. In fact, in mouse lymphoma models chemoresistance to doxorubicin caused by AKT is readily reversed by rapamycin, but PIM mediated resistance is refractory to mTORC1 inhibition. Moreover, PIM2 kinase can confer resistance of primary hematopoietic cells to rapamycin treatment. Furthermore, PIM 1 mediates resistance to AKT and PI3K/mTOR inhibition and suggests co-targeting to improve the efficacy of PI3K/AKT/mTOR inhibitors in anticancer therapy. The PI3K/AKT/mTOR and PIM pathways are activated and seem to be relevant for tumor progression in many lymphomas, leukemias and in some solid tumors. We have previously reported that the combination of PI3K inhibitor GDC-0941 with a PIM selective inhibitor, ETP-45299, was strongly synergistic in antiproliferation experiments in MV-4-11 AML cells. Therefore, combination of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors. During the course of our investigations in this field we have identified a new chemical series of compounds with dual (PIM/PI3K) and triple activity (PIM/PI3K/mTOR inhibitors). (WO2012/156756). In this work, we show the biochemical, cellular and in vivo characterization of dual PIM/PI3K ETP-539/(IBL-202) and triple PIM/PI3K/mTOR ETP-339/(IBL-301) inhibitors. These optimized lead compounds are low nanomolar pan PIM/PI3K and pan PIM/PI3K/mTOR inhibitors respectively. These dual and triple inhibitors show excellent kinase selectivity profile against a panel of 456 kinases. Both compounds have been profiled for their antiproliferative behavior. We have identified leukemia, lymphoma, colon, and NSCLC lines which exhibit a strong sensitivity to dual and triple inhibition with GI80 between 5-10 times more potent than PIM or PI3K selective reference inhibitors. Mechanistically, cells respond to dual and triple inhibitors with a clear cell cycle arrest and marked apoptosis in AML and NSCLC cell lines, and strong down regulation of biomarkers. Our dual and triple inhibitors are optimized with respect to their in vitro ADME properties and have excellent oral bioavailability. These inhibitors have been tested in vivo in xenograft (MV4:11 AML) and transgenic (KRAsV12NSCLC) cancer mouse models. Both compounds have demonstrated down regulation of biomarkers associated with their targeted profile and significant antitumor efficacy in both models after oral administration. These inhibitors have been well tolerated, with no signs of toxicity even 20 times above the efficacious dose.
These results provide the rationale for further preclinical development of ETP-539/(IBL-202 and ETP-339/(IBL-301) and the basis for a potential clinical use in AML and NSCLC tumors.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A275.
Citation Format: Carmen Blanco Aparicio, Oliver Renner, Elena Gomez-Casero, Antonio Cebriá, Nuria Ajenjo, Enara Aguirre, David Cebrián, Ma Carmen Rodriguez de Miguel, Belén Pequeño, MaIsabel Albarrán, Rosario Riesco, Ana Belén García, Rosa Alvarez, Michael O'Neill, Sonia Martinez, Joaquin Pastor. Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A275.
Collapse
Affiliation(s)
| | - Oliver Renner
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Antonio Cebriá
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Nuria Ajenjo
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Enara Aguirre
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - David Cebrián
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Belén Pequeño
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Rosario Riesco
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Rosa Alvarez
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Sonia Martinez
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Joaquin Pastor
- 1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| |
Collapse
|
47
|
Morgado-Palacin L, Llanos S, Blanco-Aparicio C, Megias D, Pastor J, Serrano M. Abstract B45: A cell-based screening to identify nucleolar disruptors in cancer cells. Cancer Res 2013. [DOI: 10.1158/1538-7445.fbcr13-b45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer cells require highly elevated levels of ribosome biogenesis to meet the demand for increased protein synthesis. Ribosome biogenesis, one of the most energy demanding processes, takes place in nucleoli. Notably, changes in number, size and morphology of nucleoli have been long recognized as a reliable feature of cancer cells. Interestingly, the nucleolus is well known to be a hub in the stress response. Approximately 70% of the ~4500 nucleolus-associated proteins are involved in functions other than ribosome biogenesis, including cell cycle control, apoptosis or DNA repair. This places the nucleolus as an important integrator between ribosome synthesis, cell cycle progression and stress signaling. A large variety of cellular insults trigger alterations in the dynamics of nucleolar proteins and/or ribosomal RNA. Stabilization of the tumor suppressor p53 has been observed as a result of the relocalization of certain ribosomal proteins in the nucleoplasm, notably L5 and L11, where they can bind and inhibit MDM2.
The aim of this work is to identify new potential anti-tumoral drugs by means of disrupting the nucleolar integrity. By using a high content cell-based screening in which nucleolar morphology is monitored by GFP-L37, we have identified several compounds that cause nucleolar disruption thereby leading cancer cells to proliferative arrest or apoptosis. Interestingly, one of our best hits is compound 2,4,7,9-tetramethylbenzo[b][1,8]naphthyridin-5-amine (TMBNA). This compound has been previously reported by other investigators to intercalate DNA and to activate p53, although the underlying molecular pathway is unknown. Our data indicates that TMBNA activates p53 through nucleolar disruption and binding of the ribosomal protein L11 to MDM2, ultimately resulting in cell cycle arrest and apoptosis. These results highlight the relevance of the nucleolus as a main target of cancer drugs.
Citation Format: Lucia Morgado-Palacin, Susana Llanos, Carmen Blanco-Aparicio, Diego Megias, Joaquin Pastor, Manuel Serrano. A cell-based screening to identify nucleolar disruptors in cancer cells. [abstract]. In: Proceedings of the Third AACR International Conference on Frontiers in Basic Cancer Research; Sep 18-22, 2013; National Harbor, MD. Philadelphia (PA): AACR; Cancer Res 2013;73(19 Suppl):Abstract nr B45.
Collapse
Affiliation(s)
| | - Susana Llanos
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Diego Megias
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Joaquin Pastor
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Manuel Serrano
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| |
Collapse
|
48
|
Gomez-Iturriaga A, Cabeza M, Pastor J, Jove J, Casaña M, Mengual J, Muñoz J, Hervas A, Henriquez I, Carvajal C. Multi-institutional Outcomes Following External Beam Radiation Therapy and Androgen Deprivation Therapy in Patients With Extreme-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Medina-Rodríguez EM, Arenzana FJ, Pastor J, Redondo M, Palomo V, García de Sola R, Gil C, Martínez A, Bribián A, de Castro F. Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cell Mol Life Sci 2013; 70:3449-62. [PMID: 23661015 PMCID: PMC11113628 DOI: 10.1007/s00018-013-1340-2] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2012] [Revised: 04/05/2013] [Accepted: 04/08/2013] [Indexed: 12/21/2022]
Abstract
During the development of the central nervous system (CNS), oligodendrocyte precursors (OPCs) are generated in specific sites within the neural tube and then migrate to colonize the entire CNS, where they differentiate into myelin-forming oligodendrocytes. Demyelinating diseases such as multiple sclerosis (MS) are characterized by the death of these cells. The CNS reacts to demyelination and by promoting spontaneous remyelination, an effect mediated by endogenous OPCs, cells that represent approximately 5-7 % of the cells in the adult brain. Numerous factors influence oligodendrogliogenesis and oligodendrocyte differentiation, including morphogens, growth factors, chemotropic molecules, extracellular matrix proteins, and intracellular cAMP levels. Here, we show that during development and in early adulthood, OPCs in the murine cerebral cortex contain phosphodiesterase-7 (PDE7) that metabolizes cAMP. We investigated the effects of different PDE7 inhibitors (the well-known BRL-50481 and two new ones, TC3.6 and VP1.15) on OPC proliferation, survival, and differentiation. While none of the PDE7 inhibitors analyzed altered OPC proliferation, TC3.6 and VP1.15 enhanced OPC survival and differentiation, processes in which ERK intracellular signaling played a key role. PDE7 expression was also observed in OPCs isolated from adult human brains and the differentiation of these OPCs into more mature oligodendroglial phenotypes was accelerated by treatment with both new PDE7 inhibitors. These findings reveal new roles for PDE7 in regulating OPC survival and differentiation during brain development and in adulthood, and they may further our understanding of myelination and facilitate the development of therapeutic remyelination strategies for the treatment of MS.
Collapse
Affiliation(s)
- E. M. Medina-Rodríguez
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, Finca “La Peraleda”, s/n, 45071 Toledo, Spain
| | - F. J. Arenzana
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, Finca “La Peraleda”, s/n, 45071 Toledo, Spain
| | - J. Pastor
- Neurofisiología Clínica, Hospital Universitario La Princesa, Madrid, Spain
| | - M. Redondo
- Instituto de Química Médica, CSIC, Juan de la Cierva, Madrid, Spain
| | - V. Palomo
- Instituto de Química Médica, CSIC, Juan de la Cierva, Madrid, Spain
| | | | - C. Gil
- Instituto de Química Médica, CSIC, Juan de la Cierva, Madrid, Spain
| | - A. Martínez
- Instituto de Química Médica, CSIC, Juan de la Cierva, Madrid, Spain
| | - A. Bribián
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, Finca “La Peraleda”, s/n, 45071 Toledo, Spain
- Institute of Bioengineering of Catalonia, Parc Cientific de Barcelona & Cell Biology Department, Universidad de Barcelona, Barcelona, Spain
| | - F. de Castro
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, Finca “La Peraleda”, s/n, 45071 Toledo, Spain
| |
Collapse
|
50
|
Pastor J, Adámek S. [Obscure gastrointestinal bleeding]. Rozhl Chir 2013; 92:424-428. [PMID: 24274343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Obscure gastrointestinal bleeding represents 5% of all cases of bleeding into the gastrointestinal tract (GIT). The cause of this type of bleeding cannot be found by gastroscopy or colonoscopy - the most common cause being bleeding from the source in the small intestine. In other cases it is bleeding from other parts of the digestive tube which has already stopped or was not noticed during admission endoscopy. Imaging methods (X-ray, CT, MRI, scintigraphy) and endoscopic methods (flexible or capsule enteroscopy) are used in the diagnosis and treatment. If, despite having used these methods, the source of bleeding is not found and the bleeding continues, or if the source is known but the bleeding cannot be stopped by radiologic or endoscopic intervention, surgical intervention is usually indicated. The article provides an overview of current diagnostic and treatment options, including instructions on how to proceed in these diagnostically difficult situations.
Collapse
|